专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050059692A1 Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one 审中-公开
标题翻译：制备17β-N- [2,5-双（三氟甲基）苯基]氨基甲酰基-4-氮杂-5α-雄甾-1-烯-3-酮的方法
公开(公告)号：US20050059692A1
公开(公告)日：2005-03-17
申请号：US10885501
申请日：2004-07-06
申请人： Manne Reddy , Gudipati Srinivasulu , Katkam Srinivas , Komati Satyanarayana , Mayur Khunt
发明人： Manne Reddy , Gudipati Srinivasulu , Katkam Srinivas , Komati Satyanarayana , Mayur Khunt
IPC分类号： C07J73/00 , A61K31/473
CPC分类号： C07J73/00
摘要： The present invention relates to a process for the preparation of Dutasteride, which is chemically known as 17β-N-[2,5-bis (trifluoromethyl) phenyl] carbamoyl-4-aza-5-α-androst-1-en-3-one and can be represented by Formula (I).
摘要翻译：本发明涉及一种化学上已知为17β-N- [2,5-双（三氟甲基）苯基]氨基甲酰基-4-氮杂-5α-雄甾-1-烯-3 并且可以由式（I）表示。

2. 发明申请

US20060142300A1 Anhydrous crystalline forms of I and II of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1- piperazinyl) 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (gatifloxacin) 审中-公开
标题翻译： 1-环丙基-6-氟-8-甲氧基-7-（3-甲基-1-哌嗪基）-4-氧代-1,4-二氢喹啉-3-羧酸（加替沙星）的I和II的无水结晶形式，
公开(公告)号：US20060142300A1
公开(公告)日：2006-06-29
申请号：US10510892
申请日：2003-04-07
申请人： Manne Reddy , Chakilam Raju , Vetukuri Venkata Naga Kali Raju , Ningam Reddy , Rapolu Kumar
发明人： Manne Reddy , Chakilam Raju , Vetukuri Venkata Naga Kali Raju , Ningam Reddy , Rapolu Kumar
IPC分类号： A61K31/496 , C07D403/02
CPC分类号： C07D215/56
摘要： The present invention relates to the novel anhydrous crystalline forms I and II of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (gatifloxacin) which can be depicted as Formula (I). The present invention also relates to methods of making the anhydrous Forms I and II of Gatifloxacin, use of the forms and methods for preparing them.
摘要翻译：本发明涉及1-环丙基-6-氟-8-甲氧基-7-（3-甲基-1-哌嗪基）-4-氧代-1,4-二氢喹啉-3-羧酸的新的无水结晶形式I和II 可以描述为式（I）的酸（加替沙星）。本发明还涉及制备加替沙星的无水形式I和II的方法，使用形式和方法来制备它们。

3. 发明申请

US20050031696A1 Oral pharmaceutical formulations of acid-labile active ingredients and process for making same 审中-公开
标题翻译：酸性不稳定活性成分的口服药物制剂及其制备方法
公开(公告)号：US20050031696A1
公开(公告)日：2005-02-10
申请号：US10830486
申请日：2004-04-22
申请人： Ujwal Kolhe , Divi Krishna , Akhilesh Dixit , Abhijit Deshmukh , Narayan Rajput , Mailatur Mohan , Manne Reddy , Muppa Kumar , Koilkonda Purender , Alieti Reddy
发明人： Ujwal Kolhe , Divi Krishna , Akhilesh Dixit , Abhijit Deshmukh , Narayan Rajput , Mailatur Mohan , Manne Reddy , Muppa Kumar , Koilkonda Purender , Alieti Reddy
IPC分类号： A61K9/20 , A61K9/28 , A61K31/4439 , A61P1/04 , A61K9/14
CPC分类号： A61K9/2886 , A61K9/2018 , A61K9/2846 , A61K31/4439
摘要： An oral pharmaceutical formulation in dosage form of acid-labile compounds, methods of treating using the formulation and a process for its production are described.
摘要翻译：描述了酸不稳定化合物的剂型的口服药物制剂，使用制剂的治疗方法及其生产方法。

4. 发明申请

US20060167274A1 Amorphous (sumatriptan) succinate 审中-公开
标题翻译：无定形（舒马曲坦）琥珀酸酯
公开(公告)号：US20060167274A1
公开(公告)日：2006-07-27
申请号：US11386608
申请日：2006-03-22
申请人： Manne Reddy , Srinivasan Rajan , Mokkarala Murthy , Achampeta Prasad
发明人： Manne Reddy , Srinivasan Rajan , Mokkarala Murthy , Achampeta Prasad
IPC分类号： C07D209/20
CPC分类号： C07D209/16
摘要： The present invention relates to an amorphous form of Sumatriptan succinate of Formula (1). The present invention also relates to process for the preparation of an amorphous form of Sumatriptan succinate. The process for the preparation of an amorphous form of Sumatriptan succinate comprises refluxing an aqueous mixture of Sumatriptan or its succinate salt in alcoholic solvents such as methanol or nitrile solvents such as acetonitrile followed by evaporation of the solvent from the filtrate. The resulting residue is triturated with water immiscible aromatic or aliphatic hydrocarbon solvents such as cyclohexane to afford an amorphous form of Sumatriptan succinate.
摘要翻译：本发明涉及式（1）的琥珀酸Sumatriptan琥珀酸的无定形形式。本发明还涉及制备无定形形式的琥珀酸Sumatriptan琥珀酸酯的方法。制备无定形琥珀酸舒马曲坦的方法包括在醇溶剂如甲醇或腈溶剂如乙腈中回流Sumatriptan或其琥珀酸盐的水混合物，然后从滤液蒸发溶剂。所得残余物与水不混溶的芳族或脂族烃溶剂如环己烷研磨，得到琥珀酸舒马替曼的无定形形式。

5. 发明申请

US20050049295A1 Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate 审中-公开
标题翻译：制备5-（2-（4-（1,2-苯并异噻唑-3-基）-1-哌嗪基）乙基）-6-氯-1,3-二氢-2H-吲哚-2-酮盐酸盐的方法（齐拉西酮盐酸盐）及其中间体
公开(公告)号：US20050049295A1
公开(公告)日：2005-03-03
申请号：US10868506
申请日：2004-06-14
申请人： Manne Reddy , Sundaram Venkatraman , Srinivasan Rajan , Sharat Narsapur , Manoj Kharkar , Surya Devarkonda , Yarraguntla Reddy , Rangineni Srinivasulu , Deepak Shukla , Pushkar Lakhekar , Uppala Rao , Mummadi Venkatesh
发明人： Manne Reddy , Sundaram Venkatraman , Srinivasan Rajan , Sharat Narsapur , Manoj Kharkar , Surya Devarkonda , Yarraguntla Reddy , Rangineni Srinivasulu , Deepak Shukla , Pushkar Lakhekar , Uppala Rao , Mummadi Venkatesh
IPC分类号： A61K31/404 , C07D209/34 , C07D209/36
CPC分类号： A61K31/404 , C07D209/34
摘要： The present invention relates to improved processes for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl) ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one and its hydrochloride, which is known as Ziprasidone hydrochloride of Formula (I) and 5-(2-Chloro acetyl)-6-chloro oxindole of Formula (IV), which is an intermediate for the preparation of 5-(2-chloro ethyl)-6-chloro oxindole of Formula (V). Ziprasidone hydrochloride of Formula (I) of the present invention is depicted by the following structure.
摘要翻译：本发明涉及制备5-（2-（4-（1,2-苯并异噻唑-3-基）-1-哌嗪基）乙基）-6-氯-1,3-二氢-2H- 吲哚-2-酮及其盐酸盐，其被称为式（I）的齐拉西酮盐酸盐和式（IV）的5-（2-氯乙酰基）-6-氯羟吲哚，其是制备5- （V）的（2-氯乙基）-6-氯羟基吲哚。本发明的式（I）的齐拉西酮盐酸盐由以下结构描绘。

6. 发明申请

US20050020608A1 Crystalline cetirizine monohydrochloride 审中-公开
标题翻译：结晶西替利嗪一盐酸盐
公开(公告)号：US20050020608A1
公开(公告)日：2005-01-27
申请号：US10809192
申请日：2004-03-25
申请人： Manne Reddy , Srinivasan Rajan , Uppala Venkata Rao , Konda Reddy
发明人： Manne Reddy , Srinivasan Rajan , Uppala Venkata Rao , Konda Reddy
IPC分类号： C07D295/088 , A61K31/495 , C07D241/04
CPC分类号： C07D295/088
摘要： A novel crystalline form of cetirizine monohydrochloride and processes for making the crystalline form as well as compositions, pharmaceutical compositions, and methods utilizing the crystalline form are described.
摘要翻译：描述了西替利嗪一盐酸盐的新型结晶形式和用于制备结晶形式的方法以及使用结晶形式的组合物，药物组合物和方法。

7. 发明申请

US20060106227A1 3-'2-(Dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof 审中-公开
标题翻译： 3' - （二甲基氨基）乙基} - 正 - 甲基-1h-吲哚-5-甲磺酰胺及其琥珀酸酯
公开(公告)号：US20060106227A1
公开(公告)日：2006-05-18
申请号：US10516897
申请日：2004-06-16
申请人： Manne Reddy , Srinivasan Rajan , Mokkarala Murthy , Achampeta Prasad
发明人： Manne Reddy , Srinivasan Rajan , Mokkarala Murthy , Achampeta Prasad
IPC分类号： C07D209/10
CPC分类号： C07D209/16
摘要： A process for the preparation of highly pure Sumatriptan id described. A process for the preparation of novel crystalline Form I and crystalline Form II of Sumatriptan succinate is described. Sumatriptan is used for alleviating the pain of migraine headaches.
摘要翻译：描述了一种制备高纯度Sumatriptan id的方法。描述了制备琥珀酸Sumatriptan的新型结晶形式I和结晶形式II的方法。舒马曲坦用于缓解偏头痛的疼痛。

8. 发明申请

US20050234103A1 Crystalline forms of rabeprazole sodium 审中-公开
标题翻译：雷贝拉唑钠的结晶形式
公开(公告)号：US20050234103A1
公开(公告)日：2005-10-20
申请号：US10505826
申请日：2003-03-25
申请人： Manne Reddy , Sajja Eswaraiah , Vijava Bolugoddu , Ramchandra Pingili , Madhusudhan Ganta
发明人： Manne Reddy , Sajja Eswaraiah , Vijava Bolugoddu , Ramchandra Pingili , Madhusudhan Ganta
IPC分类号： A61K31/4439 , C07D401/12 , C07D43/02
CPC分类号： C07D401/12
摘要： The present invention relates to novel polymorphic forms of Rabeprazole sodium. The present invention also relates to methods of making polymorphic forms of Rabeprazole sodium. Achiphex7 (Rabeprazole sodium) is an inhibitor of the gastric proton pump. It causes dose-dependant inhibition of acid secretion and is useful as an antiulcer agent. The chemical designation of Rabeprazole sodium is 2-[[[4-(3-methoxypropoxy)-3 methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole sodium. It may be represented by Formula (1).
摘要翻译：本发明涉及雷贝拉唑钠的新型多晶型物。本发明还涉及制备雷贝拉唑钠的多晶型物的方法。 Achiphex7（雷贝拉唑钠）是胃质子泵的抑制剂。它导致酸分泌的剂量依赖性抑制，并且可用作抗溃疡剂。雷贝拉唑钠的化学名称是2 - [[[4-（3-甲氧基丙氧基）-3-甲基-2-吡啶基] - 甲基]亚磺酰基] -1H-苯并咪唑钠。它可以由公式（1）表示。

9. 发明申请

US20050137227A1 Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof 有权
标题翻译：无水莫西沙星盐酸盐的结晶形式III及其制备方法
公开(公告)号：US20050137227A1
公开(公告)日：2005-06-23
申请号：US10822154
申请日：2004-04-09
申请人： Manne Reddy , Sajja Eswaraiah , Vetukuri Venkata Naga Raju , Rapolu Kumar , Ningam Srinivasreddy , Vedantham Ravindra
发明人： Manne Reddy , Sajja Eswaraiah , Vetukuri Venkata Naga Raju , Rapolu Kumar , Ningam Srinivasreddy , Vedantham Ravindra
IPC分类号： A61K31/4709 , C07D471/04
CPC分类号： C07D471/04 , A61K31/4709
摘要： A new crystalline Form III of moxifloxacin monohydrochloride and processes for making the crystalline form as well as compositions, pharmaceutical compositions, and methods utilizing the crystalline form are described.
摘要翻译：描述莫西沙星单盐酸盐的新结晶形式III和用于制备结晶形式的方法以及使用结晶形式的组合物，药物组合物和方法。

10. 发明申请

US20050059696A1 Process for the recovery of S -(+)-methyl- (2-chlorophenyl)- (6,7-dihydro- 4H-thieno [3,2-c] pyrid-5-yl) acetate hydrogen sulfate (clopidogrel bisulfate) from its (R) and mixture of (R) and (S)- isomers 审中-公开
标题翻译：回收S - （+） - 甲基 - （2-氯苯基） - （6,7-二氢-4H-噻吩并[3,2-c]吡啶-5-基）乙酸乙酯硫酸氢盐（氯吡格雷硫酸氢盐）的方法（R）和（R）和（S） - 异构体的混合物
公开(公告)号：US20050059696A1
公开(公告)日：2005-03-17
申请号：US10842702
申请日：2004-05-10
申请人： Manne Reddy , Sajja Eswaraiah , Anumula Reddy , Alla Sampath
发明人： Manne Reddy , Sajja Eswaraiah , Anumula Reddy , Alla Sampath
IPC分类号： A61K31/4743 , C07D495/04 , C07D498/02
CPC分类号： C07D495/04
摘要： A process for the recovery of compound of formula (I) where X represents hydrogen, fluoro, chloro, bromo or iodo atom, preferably 2-chloro which comprising the steps of f. preparing compound (−) or (±)-(2-chloro phenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate methyl ester hydrogen sulfate from its corresponding camphorsulfonic acid salt compound. g. transforming the obtained compound of step (a), into the compound of (2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetic acid. h. converting the compound of step (b) into racemic compound (±)-(2-chloro phenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate methyl ester hydrogen sulfate. i. resolving the obtained racemic compound of step (c), into the optically active (+)-(2-chloro phenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate methyl ester camphor sulfonic acid salt. j. further transforming the optically active (+) form compound of step (d) into their pharmaceutically acceptable salts.
摘要翻译：回收式（I）化合物的方法，其中X代表氢，氟，氯，溴或碘原子，优选2-氯，其包括以下步骤：从其相应的樟脑磺酸制备化合物（ - ）或（±） - （2-氯苯基） - （6,7-二氢-4H-噻吩并[3,2-c]吡啶-5-基）乙酸甲酯硫酸氢盐盐化合物。 G。将得到的步骤（a）的化合物转化为（2-氯苯基） - （6,7-二氢-4H-噻吩并[3,2-c]吡啶-5-基）乙酸的化合物。 H。将步骤（b）的化合物转化为外消旋化合物（±） - （2-氯苯基） - （6,7-二氢-4H-噻吩并[3,2-c]吡啶-5-基）乙酸甲酯硫酸氢盐。一世。将得到的步骤（c）的外消旋化合物拆分成光学活性（+） - （2-氯苯基） - （6,7-二氢-4H-噻吩并[3,2-c]吡啶-5-基）乙酸乙酯甲酯樟脑磺酸盐。 j。进一步将步骤（d）的光学活性（+）形式化合物转化为其药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式